Clinical Trial Update: Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tadalafil, a PDE5 inhibitor, for heart failure and pulmonary hypertension was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Pulmonary Hypertension

Drugs mentioned

• Cialis (tadalafil)

Snippet

Sponsor: Carelon Research | Conditions: Heart Failure, Pulmonary Hypertension | Phase 3 | Status: TERMINATED | Results posted: 2015-05-04